McKesson Corporation (MCK)
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
McKesson's oncology growth, GLP-1 momentum and RxTS expansion support earnings strength, but pricing reform and margin pressures pose risks.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
McKesson Corporation (MCK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
McKesson Corporation (MCK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
McKesson Q4 Earnings Call Highlights
McKesson NYSE: MCK reported a stronger fiscal fourth quarter and full fiscal 2026 performance, with executives pointing to growth across its oncology, multispecialty, pharmaceutical distribution and prescription technology businesses, while outlining plans for continued earnings growth in fiscal 2027.
MCK Stock Falls Despite Q4 Earnings Beat, Sales Miss, Margins Up
McKesson beats Q4 EPS estimates as oncology and specialty distribution growth offset revenue miss and lift segment margins.
McKesson Corporation (MCK) Q4 2026 Earnings Call Transcript
McKesson Corporation (MCK) Q4 2026 Earnings Call Transcript
Compared to Estimates, McKesson (MCK) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for McKesson (MCK) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
McKesson (MCK) Surpasses Q4 Earnings Estimates
McKesson (MCK) came out with quarterly earnings of $11.69 per share, beating the Zacks Consensus Estimate of $11.56 per share. This compares to earnings of $10.12 per share a year ago.
Should You Buy, Sell, or Hold McKesson Before Q4 Earnings?
MCK heads into Q4 earnings with strength in oncology, GLP-1 demand, and biopharma services, but softer medical-surgical trends may weigh.
McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
McKesson (MCK) Falls More Steeply Than Broader Market: What Investors Need to Know
McKesson (MCK) closed the most recent trading day at $822.63, moving 1.48% from the previous trading session.
